These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 8567966)
1. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. Wang Q; Marini JC J Clin Invest; 1996 Jan; 97(2):448-54. PubMed ID: 8567966 [TBL] [Abstract][Full Text] [Related]
2. A de novo G+1-->A mutation at the alpha 2(I) exon 16 splice donor site causes skipping of exon 16 in the cDNA of one allele of an OI type IV proband. Filie JD; Orrison BM; Wang Q; Lewis MB; Marini JC Hum Mutat; 1993; 2(5):380-8. PubMed ID: 8257992 [TBL] [Abstract][Full Text] [Related]
3. Molecular heterogeneity in osteogenesis imperfecta type I. Willing MC; Pruchno CJ; Byers PH Am J Med Genet; 1993 Jan; 45(2):223-7. PubMed ID: 8456806 [TBL] [Abstract][Full Text] [Related]
4. Reversal of aberrant splicing of beta-thalassemia allele by antisense RNA in vitro and in vivo. Zeng Y; Gu X; Chen Y; Gong L; Ren Z; Huang S Chin Med J (Engl); 1999 Feb; 112(2):107-11. PubMed ID: 11593572 [TBL] [Abstract][Full Text] [Related]
5. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays. Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737 [TBL] [Abstract][Full Text] [Related]
7. Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects. Pochampally RR; Horwitz EM; DiGirolamo CM; Stokes DS; Prockop DJ Gene Ther; 2005 Jul; 12(14):1119-25. PubMed ID: 15815702 [TBL] [Abstract][Full Text] [Related]
8. Enhanced intracellular availability and survival of hammerhead ribozymes increases target ablation in a cellular model of osteogenesis imperfecta. Smicun Y; Kilpatrick MW; Florer J; Toudjarska I; Wu G; Wenstrup RJ; Tsipouras P Gene Ther; 2003 Nov; 10(24):2005-12. PubMed ID: 14566359 [TBL] [Abstract][Full Text] [Related]
10. Gene therapy approaches for osteogenesis imperfecta. Niyibizi C; Wang S; Mi Z; Robbins PD Gene Ther; 2004 Feb; 11(4):408-16. PubMed ID: 14724682 [TBL] [Abstract][Full Text] [Related]
11. Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Gajko-Galicka A Acta Biochim Pol; 2002; 49(2):433-41. PubMed ID: 12362985 [TBL] [Abstract][Full Text] [Related]
12. [Osteogenesis imperfecta and achievements in cell and gene therapy]. Marijanović I; Radnić M; Matić I; Erceg-Ivkosić I Acta Med Croatica; 2010 Jul; 64(3):191-200. PubMed ID: 20922862 [TBL] [Abstract][Full Text] [Related]
13. Mutations in type 1 procollagen that cause osteogenesis imperfecta: effects of the mutations on the assembly of collagen into fibrils, the basis of phenotypic variations, and potential antisense therapies. Prockop DJ; Colige A; Helminen H; Khillan JS; Pereira R; Vandenberg P J Bone Miner Res; 1993 Dec; 8 Suppl 2():S489-92. PubMed ID: 8122517 [TBL] [Abstract][Full Text] [Related]
15. Defective splicing of mRNA from one COL1A1 allele of type I collagen in nondeforming (type I) osteogenesis imperfecta. Stover ML; Primorac D; Liu SC; McKinstry MB; Rowe DW J Clin Invest; 1993 Oct; 92(4):1994-2002. PubMed ID: 8408653 [TBL] [Abstract][Full Text] [Related]
16. Molecular basis of osteogenesis imperfecta and related disorders of bone. Prockop DJ; Kuivaniemi H; Tromp G Clin Plast Surg; 1994 Jul; 21(3):407-13. PubMed ID: 7924138 [TBL] [Abstract][Full Text] [Related]
17. Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice. Burch RM; Mahan LC J Clin Invest; 1991 Oct; 88(4):1190-6. PubMed ID: 1833422 [TBL] [Abstract][Full Text] [Related]
18. A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment. Davis RL; Homer VM; George PM; Brennan SO Hum Mutat; 2009 Feb; 30(2):221-7. PubMed ID: 18853456 [TBL] [Abstract][Full Text] [Related]
19. A novel RNA-splicing mutation in COL1A1 gene causing osteogenesis imperfecta type I in a Chinese family. Xia XY; Cui YX; Huang YF; Pan LJ; Yang B; Wang HY; Li XJ; Shi YC; Lu HY; Zhou YC Clin Chim Acta; 2008 Dec; 398(1-2):148-51. PubMed ID: 18755172 [TBL] [Abstract][Full Text] [Related]
20. [Repair of the splicing defect of thalassemic allele beta IVS-2-654 C-->T in cultured human erythroid cells by antisense RNA]. Gu X; Gong L; Zhang W Zhonghua Yi Xue Za Zhi; 1997 Nov; 77(11):815-8. PubMed ID: 9772473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]